Tradestie Institutional Equity Comparison Engine

MRNA vs TECH โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

TECH Overall Edge

TECH Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Bio-Techne Corp. (TECH) driven by superior Growth & Margin, Options & Structure while MRNA counters with relative strength in Valuation, Momentum & Technical. Fundamentally, MRNA trades at 23.0x Forward P/E with -80.8% operating margin (+29.2% YoY revenue) versus TECH at 42.8x Forward P/E and 21.7% operating margin (+4.6% YoY). In options structure, MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro) against TECH sits in UNCLASSIFIED (6th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MRNA
MRNA 23.0x vs TECH 42.8x Fwd P/E
Growth & Margin Winner TECH
Op Margin -80.8% vs 21.7% ยท YoY +29.2% vs +4.6%
Momentum & Technical Winner MRNA
1Y +706.5% vs +25.7% ยท 52W Pos 67% vs 99%
Options & Structure Winner TECH
CONSOLIDATION (52nd %ile IV) vs UNCLASSIFIED (6th %ile IV)
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
1M Return -3.77%
1Y Return +706.45%
Forward P/E 23.0x
Unified AI Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0
TECH NASDAQ
Bio-Techne Corp.
Biological Products, (No Disgnostic Substances)
$72.67
-0.04% 1D
Market Cap $11.4B
1M Return +0.07%
1Y Return +25.7%
Forward P/E 42.8x
Unified AI Score
55.4 / 100 HOLD
Tech 55.0 Fund 52.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MRNA +706.45% TECH +25.7% Spread: +680.75 pp (MRNA Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
MRNA TTM Op. Margin: -80.8% TECH TTM Op. Margin: 21.7%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MRNA vs TECH. Trailing 12-month operating profitability (MRNA -80.8% vs TECH 21.7%) and valuation multiples (MRNA 23.0x vs TECH 42.8x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MRNA (4) vs TECH (6)
Institutional Metric MRNA TECH Criterion Row Winner
Market Capitalization Scale $80.7B $11.4B Larger Scale MRNA
Trailing P/E Ratio Valuation 23.0x 66.7x Lower Multiple MRNA
Forward P/E Ratio Valuation 23.0x 42.8x Lower Multiple MRNA
Revenue Growth (YoY) Growth +29.2% +4.6% Higher Growth MRNA
Operating Margin (TTM) Profitability -80.8% 21.7% Higher Margin TECH
Net Profit Margin Profitability -110.5% 14.0% Higher Margin TECH
Return on Equity (ROE) Capital Efficiency -34.5% 8.3% Higher ROE TECH
52-Week Range Position Momentum 67% ($22โ€“$281) 99% ($43โ€“$73) Stronger Trend TECH
Beta / 30D Volatility Risk Regime 2.23ฮฒ ยท 78% Vol 0.33ฮฒ ยท 2% Vol Lower Realized Risk TECH
Unified Institutional Score Composite Signal 40.3 / 100 (SELL) 55.4 / 100 (HOLD) Higher Composite TECH

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MRNA vs TECH Buy Guide
MRNA CONSOLIDATION
22d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MRNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
TECH UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live TECH Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MRNA nor TECH registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.